learn HMI-115
much-hyped research compound targeting prolactin receptor in scalp
Search
forLearn
1 / 1 resultsResearch
5 / 366 resultsresearch Dienogest Versus Gonadotropin-Releasing Hormone Analogues for the Clinical Treatment of Endometriosis: An Updated Meta-Analysis
Dienogest is safer and has fewer side effects than GnRH analogues for treating endometriosis.
research Monoclonal Antibody Against Prolactin Receptor: A Randomized Placebo-Controlled Study Evaluating Safety, Tolerability, and Pharmacokinetics of Repeated Subcutaneous Administrations in Postmenopausal Women
The drug BAY 1158061 is safe, well-tolerated, and shows potential for treating diseases related to prolactin.
research The Androgen Receptor and Its Use in Biological Assays: Looking Toward Effect-Based Testing and Its Applications
Scientists have developed a new method to detect steroid abuse in athletes using cell-based tests, which could be the future of anti-doping methods.
research Aromatherapy: An Art of Healing
Aromatherapy uses essential oils to improve mood and well-being.
research Abdominal-Pelvic Pain in Female Patients with Endometriosis: A Review of the Literature
Endometriosis causes abdominal-pelvic pain, and while surgery and treatments help, pain often persists.
Community Join
5 / 31 resultscommunity How do we only have two treatments to combat hair loss at this point in time?
The post discusses frustration over the limited and not always effective treatments for hair loss, mainly Minoxidil and Finasteride. The conversation includes mentions of potential new treatments like GT20029, HMI-115, CosmeRNA, KX-826, and microneedling, but also highlights the challenges of funding and prioritizing research in this area.
community HMI-115 question about potential earliest access
Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115, a monoclonal antibody drug, is in phase 1 and 2 trials for different conditions, but its availability on the gray market is unlikely due to high production costs.
community Bayer says drug research focus no longer on women´s health ( They dismissed HMI-115 because of their focus on women´s health
Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. Bayer dismissed HMI-115 due to focus shift away from women's health.
community We are in September and heard nothing from the HMI-115 trial
The user is frustrated about not hearing any updates on the HMI-115 trial for hair loss. They are questioning if there will be any updates in the future.
community what is a realistic timeline when does hmi-115 gets released? What are they doing in the non-clinical dev. phase?
Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115 release timeline is uncertain, with possible grey market availability in 2024-2025.